Simulations Plus, Inc. (SLP) Stock

Simulations Plus, Inc. specializes in the development of advanced software solutions for drug discovery and development, leveraging artificial intelligence and machine learning technologies globally. The company operates through two key segments: Software and Services, offering a wide array of products tailored for modeling, simulation, and prediction of molecular properties.

At the forefront of its offerings is GastroPlus, a leading software that simulates the absorption and drug interaction of compounds in both human and animal systems. Complementing this, Simulations Plus provides DDDPlus and MembranePlus, specialized simulation tools. The company's portfolio extends to mechanistic and mathematical models like DILIsym, which aids in quantitative systems toxicology, along with NAFLDsym, IPFsym, RENAsym, and MITOsym for disease-specific simulations.

Simulations Plus further enhances its capabilities with the Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor (ADMET Predictor), a chemistry-based program predicting molecular properties from structural inputs. Additionally, offerings include MedChem Designer and modeling products such as MonolixSuite and PKPlus. Beyond software solutions, the company provides clinical-pharmacology consulting services, encompassing population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing for regulatory submissions.

Catering to a diverse clientele ranging from pharmaceutical and biotechnology firms to agrochemical, cosmetics, and food industries, as well as academic and regulatory agencies, Simulations Plus was founded in 1996. Headquartered in Lancaster, California, the company continues to innovate in the realm of computational modeling and simulation, supporting the advancement of drug discovery and development processes worldwide.